NV-ROBOSENSE
8.1.2020 15:02:09 CET | Business Wire | Press release
RoboSense (http://www.robosense.ai ), the leading autonomous driving LiDAR perception solution provider, announced today the world’s first public road test of a vehicle equipped with a Smart LiDAR Sensor at CES 2020 . The RoboSense Smart LiDAR car, featuring the award-winning RS-LiDAR-M1 Smart LiDAR , will be running outside the Las Vegas Convention Center daily during CES 2020, showing the latest technological progress in autonomous vehicle LiDAR. Simultaneous exhibitions will be held at RoboSense’s CES Booth #6138 at the LVCC, North Hall showcasing the real-time 3D point cloud data on a vehicle equipped with the multi solid state LiDAR fusion system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005303/en/
First MEMS Smart LiDAR Sensor to Incorporate Sensor Hardware, AI Perception Algorithms, & IC Chipsets
The RoboSense RS-LiDAR-M1 Smart LiDAR is the world’s first MEMS Smart LiDAR Sensor to incorporate sensor hardware, AI perception algorithms, and IC chipsets, transforming conventional LiDAR sensors from an information collector to a complete data analysis and comprehension system, providing essential information for autonomous vehicle decision-making faster than ever before. The RS-LiDAR-M1 is the winner of the CES Innovation Award for two consecutive years in a row, 2019 and 2020.
RoboSense Co-Partner and Vice President of R&D, Dr. Leilei Shinohara, said, “After optimization based on large amounts of data, RoboSense’s algorithm performance and software stability and reliability have proven to have many key advantages. Developed by RoboSense after more than a decade of exhaustive research in perception technology, it has combined the advantages of deep-learning-based AI algorithm with the traditional algorithms to keep functional safety. Since 2017, RoboSense’s algorithms have gained more than 100 global partners for various types of autonomous driving scenario certifications.”
At CES and on the streets of Las Vegas, the RoboSense RS-LiDAR-M1 Smart is demonstrating that it is the world’s first and only Smart LiDAR capable of real road tests on open roads .
128 Laser Beam System & Fastest Mass-produced Short-range LiDAR for Blind Spot Detection
During CES 2020, RoboSense128-beams LiDAR RS-Ruby and the short-range Blind Spot LiDAR RS-BPearl also go on public road demo, meanwhile there is also a simultaneous exhibition at RoboSense Booth. This super high-performance 128-beam LiDAR RS-Ruby possesses an ultra-high resolution of 0.1° and the range performance of 200m for a 10% reflectivity target.
The RS-BPearl, the first mass-produced short-range LiDAR for blind-spot detection, reaches the minimum detection range of less than several centimeters, with hemispheric FOV coverage of 90° * 360°, which not only precisely identifies objects around the vehicle’s body, but can also detect the actual height information in particular scenarios, such as with bridge tunnels and culverts.
RoboSense Partner Demonstrations at CES 2020
RoboSense has partnerships with numerous industry leaders who will be announcing partnerships or co-demonstrating with RoboSense at CES, including ON Semiconductor, Xilinx, Horizon, AutoX, and Freetech.
Wade Appelman, Vice President of ISG, SensL Division, ON Semiconductor, said, “The combo of RoboSense LiDAR with the ON Semiconductor RD Series SiPM family of products will perform much better than the older APD technology employed by legacy LiDAR manufacturers using mechanical scanning architectures, further enhancing the performance of the RS-LiDAR-M1 to be one of the best in the automotive LiDAR market.”
About RoboSense
The world’s leading autonomous driving LiDAR perception solution provider. http://www.robosense.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
